Thelansis

Myelodysplastic syndromes (MDS) are a group of myeloid malignancies that result in dysplastic and ineffective hematopoiesis and have a poor 5-year relative survival estimate. The only curative treatment option for MDS is stem cell transplantation following high-dose chemotherapy and total body irradiation, which, given the toxicity of the treatment regimen, is typically reserved for younger, healthier patients. MDS in older patients or those without a suitable bone marrow donor is generally limited to supportive care with transfusions, hematopoietic growth factors, or chemotherapy. The incidence of MDS patients identified as eligible for 2nd -line therapy was 3/100,000. Approximately 9,500 people per year in the United States may be candidates for 2nd -line therapy for MDS. The risk of MDS increases with advancing age; approximately 86% of patients with newly diagnosed MDS in the United States are 60 years old (median age, 76 years). Thelansis’s “Myelodys...

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production and a variable risk of transformation to acute leukemia.   Epidemiology- According to the literature review, the incidence of MDS in the US is about 4.1–4.6 cases per 100,000 population per year, with approximately 86% of patients aged ≥60years at the time of diagnosis (median age 76 years). The incidence rate is higher in men than women. The prevalence is slightly lower in Europe, with a reported 1.24–3.7 cases per 100,000 population per year.   The competitive landscape of Myelodysplastic syndromes (MDS) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Myelodysplastic syndromes (MDS) across 8 MM market from the center of Excellence/ Public/ Priv...